Brian Park, PharmD

Drug Information Specialist https://www.clinicaladvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Infectious Diseases Information Center

Lilly to Supply Bamlanivimab to US Government Pending EUA Decision

Brian Park, PharmD

October 30, 2020

Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.

Neurology Information Center

FDA Rejects Qtrypta NDA for Acute Treatment of Migraine

Brian Park, PharmD

October 29, 2020

Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.

Vaccine Information Center

Moderna: 30,000 Participants Enrolled in COVID-19 Vaccine Trial

Brian Park, PharmD

October 28, 2020

The trial is investigating the efficacy, safety, and immunogenicity of mRNA-1273 at the 100mcg dose.

Allergy and Immunology Information Center

Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials

Brian Park, PharmD

October 26, 2020

Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.

Infectious Diseases Information Center

FDA Approves Veklury as First Treatment for COVID-19

Brian Park, PharmD

October 23, 2020

The FDA approved Veklury (remdesivir; Gilead Sciences) for the treatment of COVID-19 in patients aged ≥12 years (weighing ≥40kg) requiring hospitalization.